Zentalis Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Zentalis Pharmaceuticals's earnings have been declining at an average annual rate of -23.7%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 102.3% per year.
Key information
-23.7%
Earnings growth rate
16.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 102.3% |
| Return on equity | -50.6% |
| Net Margin | -442.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Needs To Drive Business Growth Carefully
Oct 03
Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher
Jun 19We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jun 13Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit
May 09Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Apr 12We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Feb 29Zentalis: Leading WEE1 Developer After AstraZeneca's Exit
Feb 05Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?
Jan 09We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate
Oct 13We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Jun 30We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Mar 17We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Dec 01Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer
Sep 27Zentalis Pharmaceuticals has a new chief medical officer
Sep 19Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
Aug 17Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation
May 02We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jan 12We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Oct 14Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jul 02Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?
Mar 08Revenue & Expenses Breakdown
How Zentalis Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 41 | -179 | 63 | 186 |
| 30 Jun 24 | 41 | -195 | 65 | 196 |
| 31 Mar 24 | 41 | -219 | 59 | 191 |
| 31 Dec 23 | 0 | -292 | 59 | 190 |
| 30 Sep 23 | 0 | -286 | 54 | 179 |
| 30 Jun 23 | 0 | -285 | 50 | 174 |
| 31 Mar 23 | 0 | -241 | 59 | 175 |
| 31 Dec 22 | 0 | -237 | 55 | 173 |
| 30 Sep 22 | 0 | -232 | 53 | 161 |
| 30 Jun 22 | 0 | -182 | 50 | 164 |
| 31 Mar 22 | 0 | -168 | 41 | 165 |
| 31 Dec 21 | 0 | -159 | 41 | 167 |
| 30 Sep 21 | 0 | -149 | 42 | 158 |
| 30 Jun 21 | 0 | -179 | 43 | 137 |
| 31 Mar 21 | 0 | -152 | 43 | 110 |
| 31 Dec 20 | 0 | -118 | 34 | 85 |
| 30 Sep 20 | 0 | -92 | 26 | 67 |
| 30 Jun 20 | 0 | -70 | 18 | 53 |
| 31 Mar 20 | 0 | -53 | 10 | 45 |
| 31 Dec 19 | 0 | -46 | 8 | 38 |
| 31 Dec 18 | 0 | -23 | 5 | 19 |
Quality Earnings: ZNTL is currently unprofitable.
Growing Profit Margin: ZNTL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZNTL is unprofitable, and losses have increased over the past 5 years at a rate of 23.7% per year.
Accelerating Growth: Unable to compare ZNTL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZNTL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ZNTL has a negative Return on Equity (-50.61%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 16:07 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zentalis Pharmaceuticals, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Andrew Fein | H.C. Wainwright & Co. |
| Biren Amin | Jefferies LLC |